CKD-828 clinical trials
Also written CKD-828.
How each study uses CKD-828 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
2-(3,4-dimethoxyphenyl)-8-(4-hydroxy-3-methoxyphenyl)-6-methyl-2-isopropyl-6-azaoctanitrile (1) · CKD-348 (1) · Multimodality Therapy (1) · D326 (1) · D337 (1)
Studies
Open first, then newest update. How each study uses CKD-828 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mgCompletedPhase 1Chong Kun Dang PharmaceuticalNCT05881707Written as CKD-828, D064, D702
- A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05834595Written as CKD-828, D064, D701
- Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy SubjectsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT05540912Written as CKD-828 Formulation 1
- Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT04304547Written as CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
- Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) TabletStatus unknownPhase 3Chong Kun Dang PharmaceuticalNCT04388215Written as CKD-828
- CKD-828 (80/5mg) Pharmacokinetic StudyCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02358824Written as CKD-828
- CKD-828 (80/5mg) Pharmacokinetic StudyCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02250833Written as CKD-828
- Efficacy and Safety of CKD-828 to Stage 2 HypertensionCompletedPhase 3Chong Kun Dang PharmaceuticalNCT01634295Written as CKD-828 2.5/40mg
- CKD-828(80/2.5mg) Pharmacokinetic Study_2ndCompletedPhase 1Chong Kun Dang PharmaceuticalNCT01352689Written as CKD-828(FDC)
- CKD-828 (40/5mg) Pharmacokinetic StudyCompletedPhase 1Chong Kun Dang PharmaceuticalNCT01340131Written as CKD-828
- CKD-828(80/2.5mg) Pharmacokinetic StudyCompletedPhase 1Chong Kun Dang PharmaceuticalNCT01246193Written as CKD-828(FDC)